Key result
Hydroxychloroquine suppresses interleukin-1β-amplified expansion of GM-CSF-expressing CD4 T cells in acute rheumatic fever.
Why the study?
Improved treatment has been stymied by gaps in understanding key steps in the immunopathogenesis of ARF and rheumatic heart disease.
Does hydroxychloroquine suppress the dysregulated IL-1β-GM-CSF axis in peripheral blood mononuclear cells from patients with acute rheumatic fever?
Does hydroxychloroquine suppress the dysregulated IL-1β-GM-CSF axis in peripheral blood mononuclear cells from patients with acute rheumatic fever?
Hydroxychloroquine suppresses the IL-1β-driven expansion of GM-CSF-expressing CD4 T cells in acute rheumatic fever, highlighting its potential as a repurposed therapy to prevent rheumatic heart disease.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Hydroxychloroquine might be an effective agent to modify the inflammatory components (as it is immunomodulatory rather than immunosuppressive), but careful exploration through clinical trials is required to understand the potential risks of QT prolongation complicating carditis. Studies exploring the role of hydroxychloroquine are underway and future work is planned to explore the role of steroids in rheumatic chorea.”
“There is a clear need for better treatments for ARF, which could reduce the risk of subsequent rheumatic heart disease. This quest is complicated by the immune pathogenesis of ARF, which is a diffuse set of immune pathologies that differ from one person with ARF to the next, rather than a single targetable defect (as is the case in some autoimmune conditions).”
May support hydroxychloroquine repurposing in acute rheumatic fever; leaves open effects on rheumatic heart disease progression.
BACKGROUND: Acute rheumatic fever (ARF) and rheumatic heart disease are autoimmune consequences of group A streptococcus infection and remain major causes of cardiovascular morbidity and mortality around the world. Improved treatment has been stymied by gaps in understanding key steps in the immunopathogenesis of ARF and rheumatic heart disease. This study aimed to identify (1) effector T cell cytokine(s) that might be dysregulated in the autoimmune response of patients with ARF by group A streptococcus, and (2) an immunomodulatory agent that suppresses this response and could be clinically translatable to high-risk patients with ARF. METHODS: The immune response to group A streptococcus was analyzed in peripheral blood mononuclear cells from an Australian Aboriginal ARF cohort by a combination of multiplex cytokine array, flow cytometric analysis, and global gene expression analysis by RNA sequencing. The immunomodulatory drug hydroxychloroquine was tested for effects on this response. RESULTS: CD4 T cells are the major source of GM-CSF in human CD4 T cells and CXCL10, a CXCR3 ligand and potent T helper 1 chemoattractant, was elevated in sera from patients with ARF. GM-CSF has recently emerged as a key T cell-derived effector cytokine in numerous autoimmune diseases, including myocarditis, and the production of CXCL10 may explain selective trafficking of these cells to the heart. We provide evidence that interleukin-1β amplifies the expansion of GM-CSF-expressing CD4 T cells, which is effectively suppressed by hydroxychloroquine. RNA sequencing showed shifts in gene expression profiles and differentially expressed genes in peripheral blood mononuclear cells derived from patients at different clinical stages of ARF. CONCLUSIONS: Given the safety profile of hydroxychloroquine and its clinical pedigree in treating autoimmune diseases such as rheumatoid arthritis, where GM-CSF plays a pivotal role, we propose that hydroxychloroquine could be repurposed to reduce the risk of rheumatic heart disease after ARF.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2018) studied Acute rheumatic fever. Hydroxychloroquine was evaluated on Expansion of GM-CSF-expressing CD4 T cells. Hydroxychloroquine effectively suppressed the interleukin-1β-amplified expansion of GM-CSF-expressing CD4 T cells in peripheral blood mononuclear cells from patients with acute rheumatic fever.
Synapse has enriched 10 related papers. Consider them for comparative context: